Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin

Diabetes, Obesity and Metabolism

Volumn 18, Issue 8, 2016, Pages 812-819

  Rodbard, H W ^a   Seufert, J ^b   Aggarwal, N ^c   Cao, A ^d   Fung, A ^d   Pfeifer, M ^d   Alba, M ^d  

^a Endocrine and Metabolic Consultants   (United States)

^b UNIVERSITY OF FREIBURG   (Germany)

^c Aggarwal and Associates Ltd   (Canada)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

canagliflozin; sitagliptin; sodium glucose co transporter; titration; triple therapy; type 2 diabetes mellitus

Indexed keywords

CANAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; PLACEBO; SITAGLIPTIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; BLOOD LEVEL; BODY WEIGHT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DEHYDRATION; DIABETIC KETOACIDOSIS; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FRACTURE; FUNGAL GENITAL INFECTION; GLOMERULUS FILTRATION RATE; HUMAN; HYPOGLYCEMIA; KETOACIDOSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; POSITIONAL DIZZINESS; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; URINARY TRACT INFECTION; AGED; BLOOD PRESSURE; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; HYPOVOLEMIA; METABOLISM; MIDDLE AGED; MYCOSIS; TREATMENT FAILURE; TREATMENT OUTCOME;

AGED; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; HYPOVOLEMIA; MALE; METFORMIN; MIDDLE AGED; MYCOSES; REPRODUCTIVE TRACT INFECTIONS; SITAGLIPTIN PHOSPHATE; TREATMENT FAILURE; TREATMENT OUTCOME; URINARY TRACT INFECTIONS;

EID: 84973549996     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12684     Document Type: Article

References (29)

1. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38: 140–149.
2. Wu D, Li L, Liu C. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Obes Metab 2014; 16: 30–37.
3. Mishriky BM, Cummings DM, Tanenberg RJ. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract 2015; 109: 378–388.
4. Garber AJ, Abrahamson MJ, Barzilay JI et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm–2016 executive summary. Endocr Pract 2016; 22: 84–113.
5. Abdul-Ghani MA, Norton L, Defronzo RA. Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. Am J Physiol Renal Physiol 2015; 309: F889–F900.
6. Mudaliar S, Polidori D, Zambrowicz B, Henry RR. Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside. Diabetes Care 2015; 38: 2344–2353.
7. Pratley RE, Salsali A. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Curr Med Res Opin 2007; 23: 919–931.
8. ® (canagliflozin) tablets, for oral use [package insert]. Titusville: Janssen Pharmaceuticals, 2015.
9. FARXIGA™ (dapagliflozin) tablets, for oral use [package insert]. Princeton: Bristol-Myers Squibb Company, 2015.
10. ® (empagliflozin) tablets, for oral use [package insert]. Ridgefield: Boehringer Ingelheim Pharmaceuticals, Inc., 2015.
11. Stenlöf K, Cefalu WT, Kim KA et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013; 15: 372–382.
12. Stenlöf K, Cefalu WT, Kim KA et al. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr Med Res Opin 2014; 30: 163–175.
13. Wilding JP, Charpentier G, Hollander P et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract 2013; 67: 1267–1282.
14. Lavalle-González FJ, Januszewicz A, Davidson J et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 2013; 56: 2582–2592.
15. Forst T, Guthrie R, Goldenberg R et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab 2014; 16: 467–477.
16. Neal B, Perkovic V, de Zeeuw D et al. Efficacy and safety of canagliflozin, an inhibitor of sodium glucose co-transporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care 2015; 38: 403–411.
17. Fulcher G, Matthews DR, Perkovic V et al. Efficacy and safety of canagliflozin used in conjunction with sulfonylurea in patients with type 2 diabetes mellitus: a randomized, controlled trial. Diabetes Ther 2015; 6: 289–302.
18. Cefalu WT, Leiter LA, Yoon KH et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013; 382: 941–950.
19. Leiter LA, Yoon KH, Arias P et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care 2015; 38: 355–364.
20. Schernthaner G, Gross JL, Rosenstock J et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week, randomized trial. Diabetes Care 2013; 36: 2508–2515.
21. Bode B, Stenlöf K, Sullivan D, Fung A, Usiskin K. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract 2013; 41: 72–84.
22. Bode B, Stenlöf K, Harris S et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. Diabetes Obes Metab 2015; 17: 294–303.
23. Yale JF, Bakris G, Cariou B et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013; 15: 463–473.
24. Yale JF, Bakris G, Cariou B et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab 2014; 16: 1016–1027.
25. Fulcher G, Matthews DR, Perkovic V et al. Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. Diabetes Obes Metab 2016; 18: 82–91.
26. Jabbour SA, Hardy E, Sugg J, Parikh S. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care 2014; 37: 740–750.
27. National Committee on Quality Assurance. The Healthcare Effectiveness Data and Information Set (HEDIS) measures 2013. Available from URL: http://www.fchp.org/providers/resources/hedis-measures.aspx Accessed 26 May 2016.
28. Nyirjesy P, Sobel JD, Fung A et al. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin 2014; 30: 1109–1119.
29. Usiskin K, Kline I, Fung A, Mayer C, Meininger G. Safety and tolerability of canagliflozin in patients with type 2 diabetes: pooled analysis of phase 3 study results. Postgrad Med 2014; 126: 16–34.